John Burke, MD, is a hematologist, medical oncologist, and blood cancer specialist at Rocky Mountain Cancer Centers.
DLBCL: Approaches for Monitoring Frontline Treatment Response
Debates regarding the proper timing for repeat scans, interval CT testing, and surveillance imaging on patients with diffuse large B-cell lymphoma following frontline therapy.
DLBCL Risk Status and Frontline Treatment Decisions
The differences between frontline treatment strategies for early stage vs double- or triple-hit diffuse large B-cell lymphoma.
DLBCL: Frontline Therapy for GCB and ABC Subtypes
A discussion of standard frontline treatment approaches and considerations for utilizing maintenance therapy for patients with germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma.
Classifying and Stratifying Patients With DLBCL
A review of the criteria that help hematologist-oncologists appropriately manage patients with diffuse large B-cell lymphoma.
Clinical Pearls for Managing R/R DLBCL
John Burke, MD, provides clinical pearls in the recognition in treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Novel Therapies for R/R DLBCL
John Burke, MD, reflects on current novel therapies used in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
L-Mind Trial and Implications for R/R DLBCL
John Burke, MD, reviews the practical implications and role of tafasitamab and lenalidomide in addition to reviewing significant results from the L-MIND trial.
Second-line Treatment Recommendations for R/R DLBCL
John Burke, MD, considers factors for initiating second-line treatment in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Frontline Treatment Options for R/R DLBCL
John Burke, MD, discusses frontline treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Case Presentation: Diffuse Large B-cell Lymphoma
John Burke, MD, presents a case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Toxicities From Tafasitamab Monotherapy Are Less Severe After Discontinuing Lenalidomide in R/R DLBCL
The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.
Progress Made in Treating R/R DLBCL
R/R DLBCL: Treating With Tafasitamab Plus Lenalidomide
R/R DLBCL: Observations From the Re-MIND Study
Implications for Treating R/R DLBCL With the L-MIND Regimen
Current Treatment Approaches for R/R DLBCL
Frontline Treatment Approaches in DLBCL
DLBCL: Cytogenetic Testing and Treatment Initiation
Approaching DLBCL: Risk Assessment and Prognosis
Case Overview: 77-Year-Old Woman With DLBCL
A 77-Year-Old Woman with DLBCL
John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.
Deciding on Rituximab Versus Obinutuzumab in Follicular Lymphoma
John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.